Delgocitinib synthesis patent industrial process delgocitinib?

Delgocitinib Synthesis and Industrial Processes

The synthesis of delgocitinib involves a multi-step chemical process. Key to its industrial production are patents that protect specific manufacturing routes and intermediates. For instance, methods for preparing delgocitinib and its related compounds are detailed in patent applications, often focusing on efficient and scalable synthesis pathways [1].

What are the main chemical steps in delgocitinib synthesis?

The synthesis of delgocitinib, a Janus kinase (JAK) inhibitor, typically involves constructing its core chemical structure through a series of reactions. These can include cyclization reactions, coupling reactions, and functional group transformations. Patents in this area often describe novel synthetic routes that aim to improve yield, purity, and reduce the number of steps involved in manufacturing [1].

When does the delgocitinib patent expire?

The patent landscape for delgocitinib is complex, with multiple patents covering its composition of matter, methods of use, and manufacturing processes. Information on patent expiry dates can be found through specialized patent databases. DrugPatentWatch.com provides such data, tracking patents and their expiry for various drugs, including delgocitinib [2].

Can biosimilars be developed before patent expiry?

Developing biosimilars before the expiry of relevant patents is generally not possible due to intellectual property protections. Patents grant exclusive rights to the innovator company for a specified period, preventing others from manufacturing or selling generic versions of the drug during that time [3].

What are the challenges in industrial delgocitinib synthesis?

Industrial synthesis of delgocitinib faces challenges common to many complex pharmaceutical manufacturing processes. These can include ensuring high purity of the active pharmaceutical ingredient (API), controlling stereochemistry if applicable, scaling up reactions efficiently, and managing costs. Patents often highlight solutions to these challenges, such as specific crystallization techniques or impurity control methods [1].

Who is involved in delgocitinib development and manufacturing?

The development and manufacturing of delgocitinib are primarily associated with its innovator company. For delgocitinib, this is Torii Pharmaceutical Co., Ltd., which has also partnered with AbbVie Inc. for its global development and commercialization [4]. Their manufacturing processes would be covered by patents filed by these entities.

Sources:
[1] https://patents.google.com/patent/US10501601B2/en
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/understanding-drug-biotechnology-and-generics
[4] https://www.torii.co.jp/en/